

DSM Pharmaceutical Products

45 Waterview Blvd
Parsippany, NJ 07054-1298

DSM Biologics and Crucell Sign a Biopharmaceutical Manufacturing Agreement

(Parsippany – October 3, 2007)

DSM Biologics, a business unit of DSM Pharmaceutical Products (headquartered in Parsippany, NJ) and Crucell (headquartered in Leiden, Netherlands) have signed a Biopharmaceutical Manufacturing Agreement for production on the basis of the PER.C6[®] manufacturing platform of Crucell's proprietary antibody cocktail (containing two antibodies), which Crucell develops against rabies. Under the terms of the agreement, Crucell has contracted DSM Biologics, its alliance partner for the PER.C6[®] manufacturing platform, for the process validation and manufacturing of antibody batches for Phase III clinical efficacy studies. The services will be provided out of DSM Biologics' FDA-approved manufacturing facility in Groningen, The Netherlands.

"DSM Biologics is very pleased to be involved in this exciting project. The agreement is a clear recognition of the value that the PER.C6[®] manufacturing platform brings to the biopharmaceutical industry" says Karen King, President, DSM Biologics.

About the PER.C6[®] Technology Platform

Crucell's and DSM's PER.C6[®] technology platform has been developed for the large-scale manufacture of biopharmaceutical products including vaccines. Compared to conventional production technologies, the strengths of the PER.C6[®] technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

About DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6[®] human cell line as a production platform for recombinant proteins and monoclonal antibodies. The combination of the PER.C6[®] human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market.

About DSM Pharmaceutical Products

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing services to the pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical Products provides contract manufacturing services including: advanced intermediates, active ingredients (API's), amino acids and derivatives, mammalian cell culture production (fed-batch and perfusion) of monoclonal antibodies, proteins, vaccines, finished dose manufacturing of solid dose, scheduled drugs, liquids, aseptic liquid and lyophilized products.

From clinical to commercial services, DSM focuses the right resources on providing the highest level of service and quality while applying innovative solutions to satisfy customers' unique manufacturing needs.

About DSM

DSM is active worldwide in [nutritional and pharma ingredients, performance materials and industrial chemicals](#). The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named [Vision 2010 – Building on Strengths](#), focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over €8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with [locations](#) in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com.

Forward-looking statements

This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.

For more information:

DSM Pharmaceutical Products

Karen King
President
DSM Biologics
+1-973-257-8427
Karen.King@dsm.com

DSM Biologics

Marcel Lubben
Vice President
Marketing, Sales & NBD
Tel. (+31) 46 47 73343
marcel-m.lubben@dsm.com